Hormone Therapy and Risk for Venous Thromboembolism: Comments and Correction
Authors: H. Joan Waitkevicz, Deborah Axelrod
Journal: Annals of Internal Medicine (2001)

Letters2 January 2001Hormone Therapy and Risk for Venous Thromboembolism: Comments and CorrectionH. Joan Waitkevicz, MD and Deborah Axelrod, MDH. Joan Waitkevicz, MDBeth Israel Medical Center; New York, NY 10003 (Waitkevicz)St. Vincent's Hospital and Medical Center; New York, NY 10011 (Axelrod)Search for more papers by this author and Deborah Axelrod, MDBeth Israel Medical Center; New York, NY 10003 (Waitkevicz)St. Vincent's Hospital and Medical Center; New York, NY 10011 (Axelrod)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-134-1-200101020-00020 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Grady and colleagues (1) reported that in HERS, the increased risk for venous thrombosis and pulmonary embolism in women with coronary disease given postmenopausal estrogen/progestin HRT was substantially reduced by aspirin use. In this population, not surprisingly, the authors also noted that having cancer was independently associated with having a thromboembolic event.Also recently, the Pulmonary Embolism Prevention trial, a meta-analysis of 17 444 patients undergoing orthopedic surgery who were randomly assigned to receive 160 mg of aspirin daily or placebo, reported that aspirin was associated with a 36% reduction in thromboembolic events but a 58% reduction ...References1. Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, et al . Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med. 2000;132:689-96. LinkGoogle Scholar2. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000; 355:1295-302. [PMID: 0010776741] Google Scholar3. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al . Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-88. CrossrefMedlineGoogle Scholar4. Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, et al . Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 1999;91:1829-46. CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Beth Israel Medical Center; New York, NY 10003 (Waitkevicz)St. Vincent's Hospital and Medical Center; New York, NY 10011 (Axelrod) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoPostmenopausal Hormone Therapy Increases Risk for Venous Thromboembolic Disease: The Heart and Estrogen/progestin Replacement Study Deborah Grady , Nanette K. Wenger , David Herrington , Steven Khan , Curt Furberg , Donald Hunninghake , Eric Vittinghoff , Stephen Hulley , and Hormone Therapy and Risk for Venous Thromboembolism: Comments and Correction Mark R. Goldstein Hormone Therapy and Risk for Venous Thromboembolism: Comments and Correction Deborah Grady and Eric Vittinghoff Hormone Therapy and Risk for Venous Thromboembolism: Comments and Correction Roger Peverill Metrics 2 January 2001Volume 134, Issue 1Page: 80-81KeywordsAspirinBreast cancerPulmonary diseasesPulmonary embolismRandomized trialsRisk managementStrokeThromboembolismThrombosisVenous thromboembolism ePublished: 2 January 2001 Issue Published: 2 January 2001 CopyrightCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...